GGrantIndex
Sort

64,565 grants matching drug discovery

Development of a multi-omic clinical decision platform to guide personalized therapy

$525,071
Samir Parekh · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA

Development of Nucleic Acid Platform for Targeting DNA

$525,000
Danith H Ly · Carnegie Mellon University · · FY2010 · MPS

Framework to Accelerate Substance Use Disorder Genetic Studies through Customizable, EHR-Based Precision Phenotyping

$525,000
Alvin Dean Jeffery · Vanderbilt University Medical Center · DP1 · FY2025 · DA

CAREER: Development of Force-Activated Materials for the Release of Small Organic Molecules

$525,000
Andrew J Boydston · University Of Washington · · FY2015 · MPS

High-Throughput Platform for Identifying Stem Cell Toxicity

$524,983
Jonathan S. Dordick · Rensselaer Polytechnic Institute · R01 · FY2012 · ES

Depot formulation of a D-peptide HIV entry inhibitor

$524,908
Alan L Mueller · Navigen, Inc. · R56 · FY2016 · AI

Development of NMUR2 Antagonists as Novel Analgesics

$524,835
Neil Cutshall · Omeros Corporation · R44 · FY2012 · DA

Engineering the Vocal Fold Extracellular Matrix

$524,805
Susan L Thibeault · University Of Wisconsin-Madison · R01 · FY2014 · DC

JHU- Optimal regimen development on a Ribosome inhibitor backbone.

$524,782
Eric L Nuermberger · Global Alliance For Tb Drug Development · U19 · FY2019 · AI

Targeting HER2-low breast cancer with 17p loss

$524,740
Xiongbin Lu · Indiana University Indianapolis · R01 · FY2023 · CA

Targeting HER2-low breast cancer with 17p loss

$524,740
Xiongbin Lu · Indiana University Indianapolis · R01 · FY2022 · CA

Data and analysis ecosystem for eukaryotic pathogen targeted sequencing

$524,724
Bryan R Greenhouse · University Of California, San Francisco · U01 · FY2024 · AI

Multiscale Modeling for Treatment Discovery in Duchenne Muscular Dystrophy

$524,715
Silvia Salinas Blemker · University Of Virginia · U01 · FY2017 · AR

Novel antimicrobial agents to overcome antibiotic resistant Pseudomonas and MRSA respiratory infection

$524,705
Yuanpu Peter Di · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · AI

Discovery of Drugs, Targets, and Target Strategies for Immunotherapy of CLL

$524,636
Christoph Rader · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Gene Networks Essential to Colon Cancer Phenotype

$524,632
Hartmut Land · University Of Rochester · R01 · FY2011 · CA

Training program in cancer pharmacology

$524,571
Ian Alexander Blair · University Of Pennsylvania · R25 · FY2009 · CA

Developing Selective EphA2 Inhibitors for the treatment of Cancer

$524,549
Nathanael Schiander Gray · Dana-Farber Cancer Inst · R01 · FY2015 · CA

Developing Selective EphA2 Inhibitors for the treatment of Cancer

$524,549
Nathanael Schiander Gray · Dana-Farber Cancer Inst · R01 · FY2013 · CA

The Cellular Modeling Core for MARMO-AD

$524,539
Amantha Thathiah · University Of Pittsburgh At Pittsburgh · U19 · FY2025 · AG

Translational Studies on Early-life Stress and Vulnerability to Alcohol Addiction

$524,518
Jeffrey L. Weiner · Wake Forest University Health Sciences · P01 · FY2013 · AA

Development of Pre-Erythrocytic Malaria Vaccines

$524,485
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

Development of Pre-Erythrocytic Malaria Vaccines

$524,485
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI

Core B

$524,455
Bjorn E Oskarsson · Mayo Clinic Jacksonville · P01 · FY2021 · NS

New Non-Nuceleotide Reverse Transcriptase Inhibitors for Drug Resistant HIV Strains

$524,446
Chin-Ho Chen · Duke University · R01 · FY2021 · AI